Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2415
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection ; volume:22 ; number:1 ; day:29 ; month:6 ; year:2022 ; pages:1-10 ; date:12.2022
BMC ophthalmology ; 22, Heft 1 (29.6.2022), 1-10, 12.2022
- Urheber
-
Nawar, Amin E.
Wasfy, Tamer
Shafik, Heba M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12886-022-02503-x
- URN
-
urn:nbn:de:101:1-2022082020450911703456
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
17.09.2025, 15:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nawar, Amin E.
- Wasfy, Tamer
- Shafik, Heba M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study
Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study
Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study
Acquired perforating collagenosis associated with ranibizumab injection and succesfully switched to aflibercept
Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD